Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) announced on Monday that it has entered a definitive collaboration agreement with technology company Tempus AI Inc (NASDAQ: TEM) to expand access to its FDA-approved and Medicare-reimbursed prognostic test, kidneyintelX.dkd, across the Tempus network of US healthcare institutions.

The partnership will make the test more widely available to eligible patients with type 2 diabetes and chronic kidney disease, a condition affecting nearly 15 million people in the US. KidneyintelX.dkd will become the first chronic kidney disease diagnostic in the Tempus portfolio, supporting clinicians in predicting risk of progressive kidney function decline in patients with stages 1-3b disease.

Tests will be processed in Renalytix laboratories, with results reported electronically to clinicians and patients. The tool provides risk stratification insights that can guide earlier intervention and improve care outcomes in diabetes and kidney disease.

KidneyintelX.dkd has been commercially available in the US since receiving FDA approval and Medicare reimbursement, priced at USD950 per result. More than 15,000 patients have already been tested, generating real-world data showing improved diagnosis, prognosis and treatment rates. The test is also recommended in the international chronic kidney disease guidelines (KDIGO).

Uncontrolled kidney disease affects over 14 million people in the US and 8 million in the UK, representing a major burden on healthcare systems. Renalytix said its collaboration with Tempus will accelerate adoption of kidneyintelX.dkd, supporting broader integration into US clinical workflows.